2013 EACPT Geneva Congress Symposia: How to become a self-empowered patient?

-->

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on how to become a self-empowered patient

An empowered patient is defined as an individual being an active member of his/her disease management team and being able to make decisions consistent with his/her values. Thus conceived, the concept of empowerment is a real paradigm shift for patients and for health professionals. The relation between the physician and the patient is moving from a “the powered physician to the self-powered patient” and the fast growing access to Internet is accelerating the shift. This session will discuss how this new form of “Doctor-patient relationship” may impact on drug therapy and compliance as well as on clinical research.

2013 EACPT Congress

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congress Symposia: New targets for pain treatment

-->

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on new targets for pain treatment

Chronic pain and neuropathic pain in particular are a medical challenge as they are poorly responsive to classical peripheral anti-inflammatory or powerful, centrally-acting analgesics.

Since our understanding of the mechanisms generating pain has noticeably increased, the idea of targeting key molecules has emerged and a mechanism-based approach to treatment has been advocated. This concept will be discussed in this session, from a basic science point of view as well as with the clinical example of HIV neuropathy.

Oral short communications will be selected abstracts are most welcome!

2013 EACPT Congress

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congress Symposia: New developments in TDM

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on New developments in TDM

The development and implementation of rational, evidence-based approaches for the monitoring of medicinal therapies belong to the agenda of Clinical Pharmacology. The principles and challenges of therapeutic monitoring in the broad sense will be reviewed during this session. Further emphasis will be put on the monitoring of circulating drug concentrations, illustrated with the particular case of novel anticancer agents among other candidates to target drug concentration-triggered interventions. Recent developments will be presented and discussed in view of current needs for patients to benefit from the best possible dosage adjustment for drug treatments.

2013 EACPT Congress

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congess Symposia: PK/PD modeling

-->

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on PK/PD modeling

Population pharmacokinetic and pharmacodynamic modeling is used for exploratory analyses in the clinical development of new drugs or during post-marketing studies.  The advantages of such an approach are the collection of data in the target population, the assessment of the variability within this population and, hopefully, the discovery of factors that control this variability. The present and future developments of this discipline will be outlined with regard to regulatory acceptance, extension to mechanistic-based and disease progression modeling, and application to treatment optimization, exemplified by a panel of illustrative studies.

2013 EACPT Congress

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congress Symposia: Clinical trial regulation, control and benefits

-->

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on clinical trial regulation, control and benefits

In July 2012, the European Commission adopted a proposal for a Regulation on Clinical Trials. This is now under discussion by the European Parliament and the Council. Input from affected stakeholders is deemed also critical to end up in an optimised legislative framework for clinical trials in Europe. During next year the discussion process should be reaching its end. This session will be a unique opportunity to share and discuss first hand opinions from two key stakeholders intervening in clinical trials, regulatory bodies and academia, and discuss together benefits and risks associated to the legislative proposal.

2013 EACPT Congress

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congress Symposia: Inflammatory disease and biotherapeutics

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on Inflammatory disease and biotherapeutics

The development of biotherapeutics has considerably expanded during the last decade with the formidable improvement of biotechnological tools and better validation of targets. Inflammatory disorders represent indications of choice for the development of biotherapeutics. An intense competition is taking place currently to find new treatments for disorders against which the therapeutic armamentarium has remained limited for a long time. This session will focus on the latest therapeutic developments in the field of neurological and rheumatologic inflammatory disorders and discuss the promise but also the limitations of these new approaches.

2013 EACPT Congress

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congress Symposia: Drug-Drug Interactions

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on Drug-Drug Interactions

Drug-drug interaction is one of the major problems in therapeutics associated with the use of drugs. Given the aging of the population, polymedication and the continuous development of new drugs, the occurrence of clinically significant drug-drug interactions will dramatically increase. Metabolic enzymes as well as drug transporters are frequently involved in DDI. In vitro-in vivo extrapolation (IVIVE) methodology is widely used in drug discovery and huge effort in both academia and industry has focused on developing reliable methods to predict DDI. During this session, you will have the opportunity to discuss with international experts in the field the state of the art in predicting the magnitude of DDI at the individual level, the clinical pertinence and the role of transporters in drug interactions.

EACPT Congress 2103
Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Congress Symposia: Health Therapies Assessment

-->

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on Health Therapies Assessment

The UK’s National Institute of Health and Clinical Excellence (NICE) has led the way internationally in development of Health Technology Assessment (HTA), setting thresholds for acceptable cost-effectiveness, identifying factors that may modify this threshold (e.g. orphan drugs). NICE focused on disease-area treatment with multiple technology appraisals but has subsequently developed more rapid single-technology appraisal to provide authoritative clinical guidelines, quality standards, and implementation tools. Other European HTA agencies are based on relative effectiveness assessment of listed pharmaceuticals (REAL) and provide additional approaches in evaluating drug utility.

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congress Symposia: Health Economic Assessment

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on Health Economic Assessment

Personalised medicine and pharmacogenetic testing add new insights in drug development. From 2014, all new branded medicines and diagnostic tools in some European countries will be priced according to their therapeutic value and wider benefits they may deliver. Under this value-based pricing (VBP) system, it is proposed that explicit weightings be attached to the health benefits (e.g. QALY gains) provided by medicines to reflect a broader range of relevant criteria. There is controversy as to which forms of benefits are to be weighted, and by how much. The transferability issues from a country to another one will be discussed.

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

EACPT Geneva Congress Symposia: Drug-induced liver injury

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on drug-induced liver injury

Drug-induced liver injury (DILI) is a rare but clinically important problem. Many different drugs can cause DILI, with the pattern of injury varying between drugs. A better understanding of the genetic and environmental factors that are associated with DILI will allow the development of strategies to identify susceptible individuals prior to prescription. Current detection methods do not provide insight into injury mechanisms and do not allow prediction of clinical outcomes of liver injury. This session will focus on the molecular mechanisms that cause DILI, novel biomarkers for the diagnosis of DILI and current approaches towards classifying DILI within clinical studies.

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congress Symposia: Assessing and supporting tomorrow’s prescribers

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Assessing and supporting tomorrow’s prescribers

Prescribing is core business for most healthcare organisations and the major tool used to influence the course of their patients' illnesses as well as to prevent future disease. Much of the workload is undertaken by relatively junior doctors and there is accumulating evidence that avoidable adverse drug reactions and prescribing errors are common. This symposium will address several issues that are relevant to this problem. First, it will examine the development of assessments that might predict poor prescribing performance and the need for further training. Second, it will highlight how prescribing education might be improved. Third, it will look at the potential for electronic prescribing solutions to improve quality. Finally, the impact of implementing standardised prescribing documentation will be discussed.

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congress Symposia: Innovative medicine initiative

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on Innovative medicine initiative

The Innovative Medicines Initiative (IMI, www.imi.europa.eu) is the world’s largest public-private partnership in health. IMI is improving the environment for pharmaceutical innovation in Europe by creating networks of industrial and academic experts in collaborative research projects. The EU contributes €1 billion to IMI’s research programme; this is matched by in kind contributions of €1 billion from members of the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI currently supports 37 projects, many of which are producing impressive results. The projects are speeding up the development of better and safer medicines for patients by addressing major bottlenecks in drug development.

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Congress Symposia: Methodological issues in clinical trials with CNS drugs

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on Methodological issues in clinical trials with CNS drugs

Clinical trials provide the basis for the acquisition of the critical information that physicians need for rational prescribing. Therefore, clinical trials should be designed and conducted utilizing clinically meaningful procedures and endpoints and potential bias should be minimized.

Methodological issues in clinical trials of central nervous system (CNS) drugs include aspects related to study design, procedures of randomization, inclusion and exclusion criteria, treatment outcome measures, sample size, statistical power and ethical considerations.

In this respect, the use of placebo arms in randomized controlled trials remains a very controversial problem when evaluating the efficacy and safety of medications used to treat neurological or psychiatric disorders. This symposium focuses mainly on the shortcomings of clinical trials in epilepsy, neuropathic pain and schizophrenia.  

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Congress Symposia - Neuro-Psychopharmacology: filling the gaps

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on Neuro-Psychopharmacology: filling the gaps
The exact neurobiological mechanisms involved in the therapeutic action of antidepressant are not clearly understood and better knowledge may help to identify new therapeutic targets and to overcome limitations of current treatment, such as poor efficacy and slow onset of action.

Moreover most current psychotropic drugs may be considered as “dirty drugs” as they bind to many different molecular targets in the body, and therefore tend to have a wide range both of therapeutic effects and adverse effects. 
This session will discuss the neurobiology of depression as well as prediction of pharmacological effects of CNS-active agents in humans so as to fill the gap between basic science and potential clinical effectiveness. 
Oral short communications will be selected: abstracts are most welcome!

2013 EACPT Congress
Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

Abstract submission open for EACPT Geneva 2013

European Association for Clinical Pharmacology & Therapeutics: 11th International Congress

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013.

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

New EACPT Geneva 2013 Congress website  www.eacpt2013.org 

Updates on sessions at EACPT Congress, Geneva 2013

European Association for Clinical Pharmacology & Therapeutics: 11th International Congress: 

Geneva, August 28th - 31st, 2013

British Pharmacological Society Prescribing Symposium

Wednesday 28th August 2013

Session organiser: Professor Simon Maxwell

  

- First, it will examine the development of assessments that might predict poor prescribing performance and the need for further training. 

- Second, it will highlight how prescribing education might be improved. 


- Third, it will look at the potential for electronic prescribing solutions to improve quality. 


- Finally, the impact of implementing standardised prescribing documentation will be discussed.

 Registration will open 10^th November 2012. Abstract submissions on the above and other Congress themes will also open 10^th November 2012 and will close 15^th April 2013. To receive updates on the congress before registering, you can submit your email address to the congress organisers.

For further information on the August 2013 Congress

Congress Website: http://www.eacpt2013.com

Secretariat email